Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

QPI 1007

Drug Profile

QPI 1007

Alternative Names: QPI-1007; siCASP2

Latest Information Update: 22 Mar 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Quark Pharmaceuticals
  • Class Antiglaucomas; Eye disorder therapies; Neuroprotectants; Small interfering RNA
  • Mechanism of Action Caspase 2 expression inhibitors; RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Optic nerve disorders
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Angle-closure glaucoma; Optic nerve disorders

Most Recent Events

  • 22 Mar 2022 No development reported - Phase-II for Angle-closure glaucoma in USA, USA, Vietnam, Singapore (Intravitreous)
  • 22 Mar 2022 No development reported - Phase-II/III for Optic nerve disorders in Singapore, China, Italy, Australia, Israel, India, USA, Germany (Intravitreous)
  • 01 Jul 2019 Quark Pharmaceuticals terminates a phase II/III trial in Optic nerve disorders in USA, Canada, Singapore, Germany, Israel, India, Australia, Italy and China as an interim analysis did not warrant to continue the enrolment , (NCT02341560)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top